Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Experts urge baby boomers to get screened for HCV

If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening.

22 May 2013

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

21 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Joint replacement surgery might be avoidable in the future, suggest scientists

Scientists at Johns Hopkins have turned their view of osteoarthritis inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, they now have evidence that the bone underneath the cartilage is also a key player and exacerbates the damage.

20 May 2013

ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.

20 May 2013

Sorrento Therapeutics' anti-MRSA program gets NIAID support

Sorrento Therapeutics, Inc. announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including methicillin-resistant S. aureus, was renewed for the second year of a two year Phase I grant award.

18 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Two seminars and seven poster sessions, Beckman Coulter will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

From Beckman Coulter Life Sciences - Flow Cytometry 16 May 2013

RuiYi signs agreement with Genor BioPharma for development of RYI-008 in China

RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China.

16 May 2013

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.

16 May 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

CMC Biologics, RuiYi to develop a cell line for RYI-008

CMC Biologics today announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody.

14 May 2013

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.

14 May 2013

Cancers physically alter cells in lymphatic system to promote the spread of disease

Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.

14 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

HSPH researchers discover potential target to treat type 2 diabetes and other metabolic diseases

Harvard School of Public Health (HSPH) researchers have discovered that a particular type of protein (hormone) found in fat cells helps regulate how glucose (blood sugar) is controlled and metabolized (used for energy) in the liver.

8 May 2013

Study provides additional data on why RV144 vaccine failed to protect more people

Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

7 May 2013

Antibody News and Research

Further Reading

Experts urge baby boomers to get screened for HCV

Multiple studies examine ideal biomarkers for Huntington's disease

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Joint replacement surgery might be avoidable in the future, suggest scientists

ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

Sorrento Therapeutics' anti-MRSA program gets NIAID support

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

RuiYi signs agreement with Genor BioPharma for development of RYI-008 in China

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

CMC Biologics, RuiYi to develop a cell line for RYI-008

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Cancers physically alter cells in lymphatic system to promote the spread of disease

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

HSPH researchers discover potential target to treat type 2 diabetes and other metabolic diseases

Study provides additional data on why RV144 vaccine failed to protect more people

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo